Your browser doesn't support javascript.
loading
Identification and characterization of chemotherapy resistant high-risk neuroblastoma persister cells.
Grossmann, Liron D; Chen, Chia-Hui; Uzun, Yasin; Thadi, Anusha; Wolpaw, Adam J; Louault, Kevin; Goldstein, Yael; Surrey, Lea F; Martinez, Daniel; Calafatti, Matteo; Gerelus, Mark; Gao, Peng; Lee, Lobin; Patel, Khushbu; Kaufman, Rebecca S; Shani, Guy; Farrel, Alvin; Moshitch-Moshkovitz, Sharon; Grimaldi, Paris; Shapiro, Matthew; Kendsersky, Nathan M; Lindsay, Jarrett M; Casey, Colleen E; Krytska, Kateryna; Scolaro, Laura; Tsang, Matthew; Groff, David; Matkar, Smita; Kalna, Josh R; Mycek, Emily; McDevitt, Jayne; Runbeck, Erin; Patel, Tasleema; Bernt, Kathrin M; Asgharzadeh, Shahab; DeClerck, Yves A; Mosse, Yael P; Tan, Kai; Maris, John M.
Afiliación
  • Grossmann LD; Sheba Medical Center, Ramat-Gan, Israel.
  • Chen CH; Children's Hospital of Philadelphia, Philadelphia, United States.
  • Uzun Y; Pennsylvania State University, United States.
  • Thadi A; Children's Hospital of Philadelphia, United States.
  • Wolpaw AJ; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Louault K; Children's Hospital of Los Angeles, Los Angeles, CA, United States.
  • Goldstein Y; Sheba Medical Center, Israel.
  • Surrey LF; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Martinez D; Children's Hospital of Philadelphia, Philadelphia, United States.
  • Calafatti M; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Gerelus M; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Gao P; The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Lee L; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Patel K; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Kaufman RS; Children's Hospital of Philadelphia, Philadelphia, United States.
  • Shani G; Sheba Medical Center, Israel.
  • Farrel A; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.
  • Moshitch-Moshkovitz S; Sheba Medical Center, Ramat Gan, Israel.
  • Grimaldi P; Children's Hospital of Philadelphia, United States.
  • Shapiro M; Children's Hospital of Philadelphia, United States.
  • Kendsersky NM; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Lindsay JM; University of Pennsylvania, Philadelphia, PA, United States.
  • Casey CE; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Krytska K; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Scolaro L; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Tsang M; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Groff D; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Matkar S; Children's Hospital of Philadelphia, United States.
  • Kalna JR; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Mycek E; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • McDevitt J; University of Pennsylvania, Philadelphia, PA, United States.
  • Runbeck E; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Patel T; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.
  • Bernt KM; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Asgharzadeh S; University of Southern California, Los Angeles, California, United States.
  • DeClerck YA; Children's Hospital of Los Angeles, Los Angeles, CA, United States.
  • Mosse YP; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
  • Tan K; The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, United States.
  • Maris JM; Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Cancer Discov ; 2024 Jul 31.
Article en En | MEDLINE | ID: mdl-39083807
ABSTRACT
Relapse rates in high-risk neuroblastoma remain exceedingly high. The malignant cells that are responsible for relapse have not been identified, and mechanisms of therapy resistance remain poorly understood. Here, we used single nucleus RNA sequencing and bulk whole genome sequencing to identify and characterize the residual malignant persister cells that survive chemotherapy from a cohort of 20 matched diagnosis and definitive surgery tumor samples from patients treated with high-risk neuroblastoma induction chemotherapy. We show that persister cells share common mechanisms of chemotherapy escape including suppression of MYCN activity and activation of NF-κB signaling, the latter is further enhanced by cell-cell communication between the malignant cells and the tumor microenvironment. Overall, our work dissects the transcriptional landscape of cellular persistence in high-risk neuroblastoma and paves the way to the development of new therapeutic strategies to prevent disease relapse.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancer Discov Año: 2024 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancer Discov Año: 2024 Tipo del documento: Article País de afiliación: Israel